Anticancer Effects of Gut Microbiota-Derived Short-Chain Fatty Acids in Cancers

J Microbiol Biotechnol. 2023 Jul 28;33(7):849-856. doi: 10.4014/jmb.2301.01031. Epub 2023 Mar 30.

Abstract

Short-chain fatty acids (SCFAs), such as butyrate, propionate, and acetate produced by the gut microbiota have been implicated in physiological responses (defense mechanisms, immune responses, and cell metabolism) in the human body. In several types of cancers, SCFAs, especially butyrate, suppress tumor growth and cancer cell metastasis via the regulation of the cell cycle, autophagy, cancer-related signaling pathways, and cancer cell metabolism. In addition, combination treatment with SCFAs and anticancer drugs exhibits synergistic effects, increasing anticancer treatment efficiency and attenuating anticancer drug resistance. Therefore, in this review, we point out the importance of SCFAs and the mechanisms underlying their effects in cancer treatment and suggest using SCFA-producing microbes and SCFAs to increase therapeutic efficacy in several types of cancers.

Keywords: Cancer; butyrate; combination therapy; gut microbiota; short-chain fatty acids.

Publication types

  • Review

MeSH terms

  • Butyrates / pharmacology
  • Fatty Acids, Volatile / metabolism
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Neoplasms* / drug therapy
  • Propionates / metabolism

Substances

  • Fatty Acids, Volatile
  • Propionates
  • Butyrates